STAT+: Pharmalittle: We're reading about top pharma lobbyist stepping down, genes and GLP-1 drugs, and more

Steve Ubl is leaving PhRMA, the pharmaceutical industry’s most powerful lobbying group, by the end of 2026. He’s led the organization for over a decade through some of its most contentious fights: the Inflation Reduction Act’s Medicare drug price negotiations, the public backlash over insulin pricing, and now the growing scrutiny of GLP-1 costs. His departure comes at a moment when the gap between what drugs cost to make and what Americans pay for them has never been more visible.

The GLP-1 pricing debate is the sharpest example. Drugs like Wegovy and Ozempic retail above $1,000 per month. Independent analyses estimate manufacturing costs at $10 to $30. PhRMA’s standard defense is that rebates reduce the actual cost by up to 79%, and that list prices fund the R&D that creates these drugs in the first place. That argument has worked well enough to preserve the status quo for years, but it’s getting harder to sustain when Indian generics of the same molecule sell for $14/month and Lilly is pricing Foundayo at $149/month to compete.

What matters for patients is what happens next in policy. The Medicare GLP-1 Bridge program launches in July 2026, offering GLP-1 access to Medicare beneficiaries at $245/month. That program exists because of the political pressure PhRMA has been fighting. Ubl’s successor will inherit an environment where both parties in Congress want to be seen doing something about drug prices, and GLP-1 medications are the most high-profile target. Whether that translates into actual pricing reform or just more noise depends on who replaces Ubl and how aggressively the industry pushes back.

For you specifically, the leadership change at PhRMA is background context, not something that requires action. If you’re paying out of pocket, the most useful developments are already here: Foundayo at $149/month, the Zepbound KwikPen at $299 to $449/month, and telehealth providers like Ro and PlushCare that can help you navigate savings programs and insurance appeals. The lobbying fight over GLP-1 pricing will play out over years. Your prescription needs to be filled this month.

Source: STAT News

Frequently asked questions

What is the Medicare GLP-1 Bridge program?

Starting July 2026, Medicare will offer GLP-1 medications to eligible beneficiaries at $245/month through a negotiated pricing program. This is separate from standard Medicare Part D coverage, which has historically excluded weight-loss drugs. The Bridge program is time-limited and designed as a stopgap while broader Medicare coverage rules are worked out. If you’re on Medicare and interested in GLP-1 therapy, contact your Part D plan or check Medicare.gov after July 1 for enrollment details.

Why does PhRMA say rebates reduce costs by 79%?

PhRMA’s claim refers to the difference between the list price (what pharmacies are billed) and the net price (what manufacturers actually receive after rebates to insurers and pharmacy benefit managers). For a drug listing at $1,300/month, a 79% rebate would mean Novo Nordisk receives about $273 net. The problem is that these rebates don’t always reduce what patients pay at the pharmacy counter, especially for uninsured or high-deductible patients who face the full list price. The rebate system benefits insurers and PBMs more than individual patients.

Will the PhRMA leadership change affect GLP-1 prices?

Not directly or quickly. PhRMA lobbies Congress and federal agencies on behalf of the pharmaceutical industry, but it doesn’t set drug prices. The organization influences policy through campaign contributions, advertising, and legislative advocacy. A new CEO might take a more conciliatory approach to GLP-1 pricing negotiations, or double down on defending current pricing structures. Either way, the near-term price landscape for patients is shaped by manufacturer savings programs, insurance formularies, and the July 2026 Medicare Bridge program rather than PhRMA’s internal politics.

Keep reading

• PlushCare: Provider profile and pricing
• Foundayo: Full medication profile
• GLP-1 cost calculator
• Branded vs compounded GLP-1: Cost and safety